Alnylam Pharmaceuticals | ALNY - Gewinn Vor Steuern

Aktienkurs
301.30
Täglich Wechseln
-0.81 -0.27%
Monatlich
-4.68%
Jährlich
14.46%
Q2 Prognose
299.00




Gewinn Vor Steuern Veränderung Datum
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Agios Pharmaceuticals USD -109.06M 5.62M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Arrowhead Research USD 28.27M 7.85M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Moderna USD -187M 631M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 5.17B 637M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 6.23B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Takeda JPY 133.86B 105.69B 2025-12
Tectonic Therapeutic USD -18.97M 63K 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09
Xencor USD -4.27M 1.76M 2025-12